Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | S1PR1 | P21453 | 13/20 | 0.55 |
| ▸ | PDE3B | Q13370 | 1/20 | 0.50 |
| ▸ | PDE3A | Q14432 | 1/20 | 0.50 |
| ▸ | NPC1 | O15118 | 1/20 | 0.44 |
| ▸ | TP53 | P04637 | 1/20 | 0.44 |
| ▸ | RAB9A | P51151 | 1/20 | 0.44 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.44 |
| ▸ | NOTUM | Q6P988 | 3/20 | 0.41 |
| ▸ | PSMD11 | O00231 | 1/20 | 0.41 |
| ▸ | GRM5 | P41594 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1963442 | 0.86 | S1PR1 (0.56) | S1PR1NPC1TP53RAB9ASMN1; SMN2 | |
| SCHEMBL2344206 | 0.78 | DYRK3 (0.66) | S1PR1PDE3BPDE3A | |
| Acetic Acid SCHEMBL1967759 | 0.76 | DYRK3 (0.66) | S1PR1PDE3BPDE3A | |
| Acetic Acid SCHEMBL1967764 | 0.76 | DYRK3 (0.66) | S1PR1PDE3BPDE3A | |
| Acetic Acid SCHEMBL2340479 | 0.76 | DYRK3 (0.66) | S1PR1PDE3BPDE3A | |
| Acetic Acid SCHEMBL1967757 | 0.76 | DYRK3 (0.66) | S1PR1PDE3BPDE3A | |
| SCHEMBL12581648 | 0.76 | S1PR1 (0.52) | S1PR1TP53NOTUM | |
| SCHEMBL2340483 | 0.75 | DYRK3 (0.58) | S1PR1PDE3BPDE3A | |
| SCHEMBL1967762 | 0.75 | DYRK3 (0.58) | S1PR1PDE3BPDE3A | |
| SCHEMBL1966543 | 0.74 | S1PR1 (0.49) | S1PR1PDE3BPDE3ANOTUM |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2509424-A1 | NOVEL OXADIAZOLE COMPOUNDS | Abbott Laboratories (US) | 2012-10-17 | — | — | EP | disclosed |
| US-20110207704-A1 | Novel Oxadiazole Compounds | ABBOTT LABORATORIES (US) | 2011-08-25 | — | — | US | disclosed |
| US-20110207704-A1 | Novel Oxadiazole Compounds | ABBOTT LABORATORIES (US) | 2011-08-25 | — | — | US | disclosed |
| US-20110207704-A1 | Novel Oxadiazole Compounds | ABBOTT LABORATORIES (US) | 2011-08-25 | — | — | US | disclosed |
| WO-2011071570-A1 | NOVEL OXADIAZOLE COMPOUNDS | ABBOTT LABORATORIES (US) | 2011-06-16 | — | — | WO | disclosed |
| WO-2011071570-A1 | NOVEL OXADIAZOLE COMPOUNDS | ABBOTT LABORATORIES (US) | 2011-06-16 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110207704-A1 | Novel Oxadiazole Compounds | S1PR3, S1PR1, S1PR2 | S1PR1 2/4885PDE3B 214/4885PDE3A 220/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.